"Thrombocytopenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subnormal level of BLOOD PLATELETS.
Descriptor ID |
D013921
|
MeSH Number(s) |
C15.378.140.855
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thrombocytopenia".
Below are MeSH descriptors whose meaning is more specific than "Thrombocytopenia".
This graph shows the total number of publications written about "Thrombocytopenia" by people in this website by year, and whether "Thrombocytopenia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 3 | 5 |
1995 | 1 | 2 | 3 |
1996 | 1 | 6 | 7 |
1997 | 2 | 5 | 7 |
1998 | 4 | 5 | 9 |
1999 | 2 | 3 | 5 |
2000 | 5 | 5 | 10 |
2001 | 4 | 2 | 6 |
2002 | 2 | 9 | 11 |
2003 | 12 | 5 | 17 |
2004 | 8 | 4 | 12 |
2005 | 9 | 6 | 15 |
2006 | 2 | 10 | 12 |
2007 | 9 | 9 | 18 |
2008 | 10 | 4 | 14 |
2009 | 7 | 9 | 16 |
2010 | 7 | 7 | 14 |
2011 | 4 | 8 | 12 |
2012 | 1 | 7 | 8 |
2013 | 5 | 7 | 12 |
2014 | 8 | 6 | 14 |
2015 | 8 | 11 | 19 |
2016 | 4 | 8 | 12 |
2017 | 7 | 9 | 16 |
2018 | 12 | 3 | 15 |
2019 | 10 | 6 | 16 |
2020 | 7 | 5 | 12 |
2021 | 9 | 6 | 15 |
2022 | 14 | 0 | 14 |
2023 | 13 | 0 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombocytopenia" by people in Profiles.
-
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist. 2023 Dec 11; 28(12):1100-e1292.
-
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro Oncol. 2023 12 08; 25(12):2262-2272.
-
SERUM HUMANIN IN PEDIATRIC SEPTIC SHOCK-ASSOCIATED MULTIPLE-ORGAN DYSFUNCTION SYNDROME. Shock. 2024 Jan 01; 61(1):83-88.
-
A familial deletion of 10p12.1 associated with thrombocytopenia. Am J Med Genet A. 2024 Jan; 194(1):77-81.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder Cancer. Gan To Kagaku Ryoho. 2023 Sep; 50(9):985-992.
-
Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023 07 25; 7(14):3582-3591.
-
Comparison of Platelet Mass Index to Platelet Count as Transfusion Trigger in Neonatal Extracorporeal Membrane Oxygenation. Clin Lab. 2023 Jul 01; 69(7).
-
Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death Dis. 2023 06 23; 14(6):371.
-
Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors. Br J Cancer. 2023 08; 129(2):266-274.